These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 1407000)

  • 21. Newer thrombolytic agents.
    Verstraete M
    Ann Acad Med Singap; 1999 May; 28(3):424-33. PubMed ID: 10575530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current clinical use of reteplase for thrombolysis. A pharmacokinetic-pharmacodynamic perspective.
    Martin U; Kaufmann B; Neugebauer G
    Clin Pharmacokinet; 1999 Apr; 36(4):265-76. PubMed ID: 10320949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and thrombolytic properties of a nonglycosylated mutant of human tissue-type plasminogen activator, lacking the finger and growth factor domains, in dogs with copper coil-induced coronary artery thrombosis.
    Cambier P; van de Werf F; Larsen GR; Collen D
    J Cardiovasc Pharmacol; 1988 Apr; 11(4):468-72. PubMed ID: 2453751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator bm 06.022 in healthy volunteers.
    Martin U; von Möllendorff E; Akpan W; Kientsch-Engel R; Kaufmann B; Neugebauer G
    Thromb Haemost; 1991 Nov; 66(5):569-74. PubMed ID: 1725068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thrombolytic properties of human tissue-type plasminogen activator, single-chain urokinase-type plasminogen activator, and synergistic combinations in venous thrombosis models in dogs and rabbits.
    Spriggs DJ; Stassen JM; Hashimoto Y; Collen D
    Blood; 1989 Apr; 73(5):1207-12. PubMed ID: 2495034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reteplase. A review of its pharmacological properties and clinical efficacy in the management of acute myocardial infarction.
    Noble S; McTavish D
    Drugs; 1996 Oct; 52(4):589-605. PubMed ID: 8891469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits.
    Collen D; Stassen JM; Larsen G
    Blood; 1988 Jan; 71(1):216-9. PubMed ID: 3120823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of pharmacokinetics of lanoteplase and alteplase during acute myocardial infarction.
    Kostis JB; Dockens RC; Thadani U; Bethala V; Pepine C; Leimbach W; Vachharajani N; Raymond RH; Stouffer BC; Tay LK; Shyu WC; Liao WC
    Clin Pharmacokinet; 2002; 41(6):445-52. PubMed ID: 12074692
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protein engineering of novel plasminogen activators with increased thrombolytic potency in rabbits relative to activase.
    Larsen GR; Timony GA; Horgan PG; Barone KM; Henson KS; Angus LB; Stoudemire JB
    J Biol Chem; 1991 May; 266(13):8156-61. PubMed ID: 1708773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hirudin and sulotroban improve coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary artery thrombosis.
    Martin U; Sponer G; Strein K
    Int J Hematol; 1992 Oct; 56(2):143-53. PubMed ID: 1421176
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis.
    Martin U; Dörge L; Fischer S
    Br J Pharmacol; 1996 May; 118(2):271-6. PubMed ID: 8735626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thrombolysis of canine femoral artery thrombus by a novel modified tissue-type plasminogen activator (E6010).
    Suzuki N; Suzuki S; Nagaoka N; Mizuo H; Yuzuriha T; Yoshitake S; Kanmatuse K
    Jpn J Pharmacol; 1994 Jul; 65(3):257-63. PubMed ID: 7799526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SSR182289A enhances thrombolysis induced by fibrinolytic agents in rabbit models of venous and arterial thrombosis.
    Visconte C; Sainte-Marie M; Lorrain J; Millet L; O'Connor SE; Schaeffer P; Herbert JM
    J Thromb Haemost; 2004 Apr; 2(4):629-36. PubMed ID: 15102019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
    Collen D; Stassen JM; Yasuda T; Refino C; Paoni N; Keyt B; Roskams T; Guerrero JL; Lijnen HR; Gold HK
    Thromb Haemost; 1994 Jul; 72(1):98-104. PubMed ID: 7974384
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biochemical, thrombolytic and pharmacokinetic properties of rt-PA P47G, K49N, a substitution variant of human tissue-type plasminogen activator.
    Nelles L; Li XK; Vanlinthout I; De Cock F; Lijnen HR; Collen D
    Thromb Haemost; 1992 Apr; 67(4):445-52. PubMed ID: 1631793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.
    Collen D; Stassen JM; De Cock F
    Thromb Haemost; 1987 Oct; 58(3):943-6. PubMed ID: 3124288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thrombolytic activity of a novel modified tissue-type plasminogen activator, YM866, in a canine model of coronary artery thrombosis.
    Kawasaki T; Katoh M; Kaku S; Gushima H; Takenaka T; Yui Y; Kawai C
    Jpn J Pharmacol; 1993 Sep; 63(1):9-16. PubMed ID: 8271535
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative time course of thrombolysis induced by intravenous boluses and infusion of staphylokinase and tissue plasminogen activator in a rabbit arterial thrombosis model.
    Helft G; Bara L; Bloch MF; Samama MM
    Blood Coagul Fibrinolysis; 1998 Jul; 9(5):411-7. PubMed ID: 9712289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The usefulness of systemic administration of recombinant human tissue-type plasminogen activator in femoral arterial thrombolysis of rabbits.
    Mino T; Suzuki J; Hayashi H
    Jpn J Pharmacol; 1989 Aug; 50(4):429-33. PubMed ID: 2476578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro stability of a tissue-type plasminogen activator mutant, BM 06.022, in human plasma.
    Rijken DC; Groeneveld E; Barrett-Bergshoeff MM
    Thromb Haemost; 1994 Dec; 72(6):906-11. PubMed ID: 7740462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.